Výsledky vyhledávání

Akademický článek

Melissa officinalis L. extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial

Autor: S Akhondzadeh, M Noroozian, MR Mohammadi, S Ohadinia, A Jamshidi, M Khani

Publikováno v: Journal of Medicinal Plants, Vol 1, Iss 4, Pp 47-57 (2002)

Alzheimer’s disease is a relentlessly progressive disease with cognitive, functional and behavioral changes over time. Current research into new drugs is focused on agents that will prevent, slow down and/or halt the progress of the disease process

Externí odkaz: https://doaj.org/article/0dd0eae37c544d50a9cb5a655098b1c2

Zobrazit plný text záznamu

Akademický článek

Salvia officinalis extract in the treatment of mild to moderate Alzheimer’s Disease: A placebo-controlled, randomized and double blind clinical trial.

Autor: Sh Akhondzadeh, M Norouzian, MR Mohammadi, S Ohadinia, AH Jamshidi, M Khani

Publikováno v: Journal of Medicinal Plants, Vol 1, Iss 3, Pp 33-43 (2002)

New treatments were presented for management of Alzheimer’s Disease (AD) in the recent years. However, they were not fully successful. The objective of this study was to assess the efficacy and safety of Salvia officinalis extract in AD at 4 months

Externí odkaz: https://doaj.org/article/34d340b3c27f4a9a86d3d135835fe15e

Zobrazit plný text záznamu

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial

Autor: A H Jamshidi, Maryam Noroozian, Mohammad Reza Mohammadi, S Ohadinia, Shahin Akhondzadeh, M Khani

Publikováno v: Journal of Clinical Pharmacy and Therapeutics. 28:53-59

Objective: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer’s disease. Design: A four month, parallel group, placebo controlled trial undertaken in three

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b3ddefaaefb3a2f27565d7db2bf10d1d
https://doi.org/10.1046/j.1365-2710.2003.00463.x

Zobrazit plný text záznamu

Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial

Autor: Ladan Kashani, Elaheh Sahimi Izadian, S. Ohadinia, Shahin Akhondzadeh, Mohammad Reza Mohammadi

Publikováno v: Journal of clinical pharmacy and therapeutics. 29(2)

Attention-deficit hyperactivity disorder (ADHD) is a common disorder of childhood that affects 3-6% of school children. Conventional stimulant medications are recognized as useful symptomatic treatments by both specialists and parents. Nevertheless,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec49c0d52382944e8e3ebbbd0b07a36
https://pubmed.ncbi.nlm.nih.gov/15068402

Zobrazit plný text záznamu

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

Autor: Shahin Akhondzadeh, Maryam Noroozian, S Ohadinia, Mohammad Reza Mohammadi, M Khani, A H Jamshidi

Publikováno v: Journal of neurology, neurosurgery, and psychiatry. 74(7)

To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer's disease.A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Ira

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e5f513b90d0e45f271b35637af72bf1
https://pubmed.ncbi.nlm.nih.gov/12810768

Zobrazit plný text záznamu

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial

Autor: S, Akhondzadeh, M, Noroozian, M, Mohammadi, S, Ohadinia, A H, Jamshidi, M, Khani

Publikováno v: Journal of clinical pharmacy and therapeutics. 28(1)

Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food and Drug Administration for the treatment of Alzheimer's disease. All

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::56b7d855d24a0a5642382393d167ab68
https://pubmed.ncbi.nlm.nih.gov/12605619

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání